Multicentre validation of CT grey-level co-occurrence matrix features for overall survival in primary oesophageal adenocarcinoma

Author:

O’Shea Robert,Withey Samuel J.,Owczarczyk Kasia,Rookyard Christopher,Gossage James,Godfrey Edmund,Jobling Craig,Parsons Simon L.,Skipworth Richard J. E.,Goh VickyORCID, ,Fitzgerald Rebecca C.,Edwards Paul A. W.,Grehan Nicola,Nutzinger Barbara,Redmond Aisling M.,Abbas Sujath,Freeman Adam,Smyth Elizabeth C.,O’Donovan Maria,Miremadi Ahmad,Malhotra Shalini,Tripathi Monika,Cheah Calvin,Coles Hannah,Eldridge Matthew,Secrier Maria,Devonshire Ginny,Jammula Sriganesh,Davies Jim,Crichton Charles,Carroll Nick,Hardwick Richard H.,Safranek Peter,Hindmarsh Andrew,Sujendran Vijayendran,Hayes Stephen J.,Ang Yeng,Sharrocks Andrew,Preston Shaun R.,Bagwan Izhar,Save Vicki,O’Neill J. Robert,Tucker Olga,Beggs Andrew,Taniere Philippe,Puig Sonia,Contino Gianmarco,Underwood Timothy J.,Grace Ben L.,Lagergren Jesper,Davies Andrew,Chang Fuju,Mahadeva Ula,Ciccarelli Francesca D.,Sanders Grant,Chan David,Cheong Ed,Kumar Bhaskar,Sreedharan Loveena,Soomro Irshad,Kaye Philip,Saunders John,Lovat Laurence,Haidry Rehan,Scott Michael,Sothi Sharmila,Hanna George B.,Peters Christopher J.,Moorthy Krishna,Grabowska Anna,Turkington Richard,McManus Damian,Coleman Helen,Petty Russell D.,Bartlett Freddie,Crosby Tom D. L.

Abstract

Abstract Background Personalising management of primary oesophageal adenocarcinoma requires better risk stratification. Lack of independent validation of proposed imaging biomarkers has hampered clinical translation. We aimed to prospectively validate previously identified prognostic grey-level co-occurrence matrix (GLCM) CT features for 3-year overall survival. Methods Following ethical approval, clinical and contrast-enhanced CT data were acquired from participants from five institutions. Data from three institutions were used for training and two for testing. Survival classifiers were modelled on prespecified variables (‘Clinical’ model: age, clinical T-stage, clinical N-stage; ‘ClinVol’ model: clinical features + CT tumour volume; ‘ClinRad’ model: ClinVol features + GLCM_Correlation and GLCM_Contrast). To reflect current clinical practice, baseline stage was also modelled as a univariate predictor (‘Stage’). Discrimination was assessed by area under the receiver operating curve (AUC) analysis; calibration by Brier scores; and clinical relevance by thresholding risk scores to achieve 90% sensitivity for 3-year mortality. Results A total of 162 participants were included (144 male; median 67 years [IQR 59, 72]; training, 95 participants; testing, 67 participants). Median survival was 998 days [IQR 486, 1594]. The ClinRad model yielded the greatest test discrimination (AUC, 0.68 [95% CI 0.54, 0.81]) that outperformed Stage (ΔAUC, 0.12 [95% CI 0.01, 0.23]; p = .04). The Clinical and ClinVol models yielded comparable test discrimination (AUC, 0.66 [95% CI 0.51, 0.80] vs. 0.65 [95% CI 0.50, 0.79]; p > .05). Test sensitivity of 90% was achieved by ClinRad and Stage models only. Conclusions Compared to Stage, multivariable models of prespecified clinical and radiomic variables yielded improved prediction of 3-year overall survival. Clinical relevance statement Previously identified radiomic features are prognostic but may not substantially improve risk stratification on their own. Key Points • Better risk stratification is needed in primary oesophageal cancer to personalise management. • Previously identified CT features—GLCM_Correlation and GLCM_Contrast—contain incremental prognostic information to age and clinical stage. • Compared to staging, multivariable clinicoradiomic models improve discrimination of 3-year overall survival.

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3